Glaucoma Surgery Explained: Trabeculectomy vs. MIGS Outcomes and Risks

Living with glaucoma means living with a constant, silent threat to your vision. You might not feel pain, but the damage is happening. When eye drops and laser treatments stop working, surgery becomes the next step. But which one? The choice between traditional trabeculectomy, a powerful procedure from the 1960s, and modern Minimally Invasive Glaucoma Surgery (MIGS), designed for safety and speed, is complex. It’s not just about lowering pressure; it’s about balancing risk against reward.

This guide breaks down the reality of these surgeries. We look at the numbers, the recovery times, and the specific outcomes you can expect in 2026. Whether you are facing advanced disease or early-stage pressure spikes, understanding these options helps you make an informed decision with your ophthalmologist.

Understanding the Goal: Lowering Intraocular Pressure

The core problem in glaucoma is high intraocular pressure (IOP). Think of IOP like water pressure in a hose. If the pressure gets too high, it damages the optic nerve-the cable that sends visual data to your brain. Once that nerve dies, the vision loss is permanent. Surgery aims to lower this pressure to a "target" level where no further damage occurs.

For decades, the goal was simply to get the number down. Today, the approach is more nuanced. Surgeons consider how much pressure needs to drop, how quickly you need recovery, and what risks you are willing to accept. This shift has led to a diverse toolkit, ranging from aggressive filtration surgeries to tiny micro-stents.

Trabeculectomy: The Gold Standard for Power

Trabeculectomy is the historical benchmark for glaucoma surgery. Developed by British ophthalmologist John Cairns in the 1960s, it remains the go-to option for patients who need significant pressure reduction. According to data from Mass Eye and Ear in 2023, this procedure lowers IOP by 30-50% in 80-90% of cases. That is a massive drop, often bringing pressure into the single digits (5-15 mmHg).

How does it work? The surgeon creates a small flap in the sclera (the white part of the eye) and removes a tiny piece of the trabecular meshwork, the eye's natural drainage system. This creates a new channel, called a fistula, allowing fluid to drain out into a reservoir under the conjunctiva, known as a bleb. It’s effective, but it’s also invasive.

The trade-off is clear. While trabeculectomy offers superior control for advanced glaucoma, it carries higher risks. Serious complications occur in 5-15% of cases. These can include hypotony (pressure getting too low), endophthalmitis (a serious infection), and bleb leaks. Postoperative care is intense, requiring 3-6 months of close monitoring, including procedures like suture lysis or bleb needling to keep the drainage open.

MIGS: Safety and Speed for Mild-to-Moderate Cases

Minimally Invasive Glaucoma Surgery (MIGS) represents a paradigm shift. Emerging around 2012 with the FDA approval of the iStent, MIGS focuses on safety and quick recovery. By January 2025, MIGS accounted for approximately 65% of all standalone glaucoma surgeries in the United States, reflecting its growing popularity.

MIGS devices use micro-incisions, typically less than 1.5mm wide. They are often performed through the same incision used for cataract surgery, making them a convenient add-on. Common devices include the iStent inject (two 1mm stents), the Hydrus Microstent (an 8mm scaffold), and the Xen Gel Stent (a 6mm gel implant). These devices bypass blocked drainage channels without creating large external wounds.

The benefits are substantial. Complication rates are low, generally under 5%. Visual recovery is fast-often within 1-2 weeks compared to 4-6 weeks for trabeculectomy. However, the pressure reduction is more modest, averaging 20-30%. Target pressures usually land between 15-18 mmHg. This makes MIGS ideal for mild-to-moderate glaucoma where extreme pressure drops aren't necessary.

Comparing Outcomes: What Do the Numbers Say?

To choose the right path, you need to compare the hard data. Here is how the two main surgical approaches stack up based on recent clinical evaluations.

Notice the cost difference. While MIGS feels like a premium option due to faster recovery, devices like the Xen Gel Stent can cost significantly more than traditional trabeculectomy. However, the long-term value depends on whether you avoid expensive medications or need secondary surgeries later.

The Role of Laser Therapy: SLT as First-Line Defense

Before considering any surgery, most patients now undergo Selective Laser Trabeculoplasty (SLT). The landmark LiGHT trial, cited extensively at the AAO 2025 conference, showed that SLT is non-inferior to eye drops for primary open-angle glaucoma. At three years, 75.3% of patients treated with SLT maintained target IOP, compared to 73.2% on medication.

Dr. Joel S. Schuman, Chair of Ophthalmology at NYU Langone Health, noted at AAO 2025 that SLT is now the preferred first-line therapy. It takes only 5-10 minutes, has no downtime, and can be repeated if needed. Newer iterations like Direct Selective Laser Trabeculoplasty (DSLT) treat 360° automatically without eye contact, though they may cause slightly more post-op irritation. If SLT fails, then the conversation shifts to MIGS or trabeculectomy.

Who Is the Right Candidate for Each Procedure?

Your anatomy, age, and disease severity dictate the best choice. There is no one-size-fits-all solution.

• Advanced Glaucoma: If you have severe nerve damage and need very low target pressures (<15 mmHg), trabeculectomy or tube shunts remain the gold standard. MIGS likely won’t provide enough pressure drop.
• Mild-to-Moderate Glaucoma: If your pressure is manageable but meds are failing, MIGS offers a great balance of efficacy and safety. It’s particularly popular among younger patients who want to avoid lifelong drops.
• Cataract Patients: If you already need cataract surgery, adding a MIGS device is highly efficient. It addresses both issues in one session with minimal added risk.
• Younger Patients: Young eyes heal aggressively, which can cause trabeculectomy blebs to scar over and fail. MIGS or tube shunts are often preferred here to avoid scarring complications.

Risks and Realistic Expectations

No surgery is risk-free. Understanding potential pitfalls helps manage expectations.

With trabeculectomy, the biggest fear is endophthalmitis, a rare but sight-threatening infection. The risk is 0.5-2.0% long-term. Bleb leaks (10-15%) and bleb failure (10-20% at 5 years) are also common challenges. You must be diligent with hygiene and follow-up visits.

MIGS has fewer catastrophic risks, but it isn't perfect. Device occlusion or migration can occur. Long-term data is still maturing; as Mass Eye and Ear notes, "long-term data regarding safety and outcomes are limited" due to the field's rapid growth. Some patients may still need additional interventions after five years.

Future Trends: Biointerventional Surgery

The landscape is evolving. By 2026, we are seeing the rise of biointerventional glaucoma surgery, particularly in the suprachoroidal space. Suprachoroidal shunts are emerging as promising standalone options, offering a middle ground between MIGS and trabeculectomy. These procedures aim to reduce inflammation and improve long-term patency. As technology advances, the trend is clearly toward earlier intervention with less invasive tools, reserving major surgery for when it’s absolutely necessary.